TD-HW755026

Prasinezumab(TD-HW755026) is a research-grade recombinant antibody targetingAlpha-synuclein. Produced in mammalian cells with native-like glycosylation.HighlightsResearch Grade— For PK/PD studies, assay development, and ADA research.Native Glycosylation— Mammalian expression ensures native-like patterns.

Human

ELISA, Bioactivity: FACS, Functional assay, Research in vivo

Humanized

IgG1-kappa

Monoclonal

Alpha-synuclein, PARK1, Non-A4 component of amyloid precursor, NACP, Non-A beta component of AD amyloid, SNCA

Please contact the lab for this information.

>95% purity as determined by SDS-PAGE.

Protein A/G purified from cell culture supernatant.

P37840

Liquid

0.01M PBS, pH 7.4.Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.

PRX002, RG-7935, 1960462-19-4

Cinpanemab is a human-derived monoclonal antibody directed against α-synuclein. Genetic and pathology evidence implicate this protein in the molecular pathogenesis of Parkinson's disease (PD) and other α-synucleinopathies such as dementia with Lewy bodies (DLB). In 2010, Biogen licensed cinpanemab from Neurimmune. The antibody was generated with reverse translational medicine technology from naturally occurring, presumably protective antibodies found in healthy aged donors, as were aducanumab and other antibodies in the Biogen-Neurimmune partnership. The antibody, previously known as BIIB054, binds to α-synuclein residues 1-10, with 800-fold higher affinity for aggregated over monomeric α-synuclein. The antibody inhibits α-synuclein spreading in cell-based assays, and slows pathology and motor symptoms in mice (Weihofen et al., 2019).• Direct evidence for ultrastructures of the α-synuclein-associated synaptic vesicle pool in presynaptic terminals., PMID:39233262• Progress in the pathogenesis and genetics of Parkinson's disease., PMID:18426756• Genetics of Parkinson disease., PMID:15717024• [Genetic factors associated with dementia in Parkinson's disease (PD)]., PMID:25739491• Analysis of GWAS-linked loci in Parkinson disease reaffirms PARK16 as a susceptibility locus., PMID:20697102• Molecular findings in familial Parkinson disease in Spain., PMID:12056932• Are genetic and sporadic Parkinson's disease patients equally susceptible to develop dementia?, PMID:19740488• Caenorhabditis elegans as an experimental tool for the study of complex neurological diseases: Parkinson's disease, Alzheimer's disease and autism spectrum disorder., PMID:22068627• TRAF6 promotes atypical ubiquitination of mutant DJ-1 and alpha-synuclein and is localized to Lewy bodies in sporadic Parkinson's disease brains., PMID:20634198• Positron emission tomography changes in PARK1 mutation., PMID:16211612

SDS-PAGE for Research Grade Prasinezumab.　　|　SEC-HPLC detection for Research Grade Prasinezumab.　　|　Detects SNCA in indirect ELISAs.　　|　Western blot analysis was performed using anti-SNCA monoclonal antibody at 1μg/ml on various samples.Lane 1:recombinant human SNCA (Catalog No:TD-HW755012), 50ngLane 2:recombinant human SNCA (Catalog No:TD-HW755012), 30ngLane 3:recombinant human SNCA (Catalog No:TD-HW755012), 20ngLane 4:recombinant human SNCA (Catalog No:TD-HW755012), 10ng

For research use only. Not suitable for clinical or therapeutic use.